<DOC>
	<DOCNO>NCT01857232</DOCNO>
	<brief_summary>Comparison efficacy APD403 prevent delayed sickness patient receive cancer chemotherapy</brief_summary>
	<brief_title>Dose-finding Study APD403 Prevent Nausea Vomiting After Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<criteria>Inclusion criterion Male female patient ≥ 18 year age Ability willingness give write informed consent Patients schedule receive , day 1 chemotherapy , either : ( ) first cisplatin chemotherapy infusion dose ≥70 mg/m2 ( male female ) ; ( ii ) first infusion cyclophosphamide dose 5001500 mg/m2 combination either epirubicin dose 60100 mg/m2 doxorubicin dose 4060 mg/m2 ( female ) Karnofsky performance score ≥ 60 % Adequate cardiac , hepatic renal function QTc interval &lt; 500 m Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &lt; 5 x upper limit normal ( ULN ) Bilirubin &lt; 5 x ULN Creatinine &lt; 3 x ULN Adequate haematological function Haemoglobin ≥ 8 g/dL White blood count ≥ 3.0 x 109/L Platelet count ≥ 100 x 109/L For female childbearing potential : ability willingness use highly effective form contraception ( e.g. , abstinence sexual intercourse , surgical sterilisation ( subject partner ) doublebarrier method contraception either intrauterine device ( IUD ) occlusive cap spermicide , conjunction partner 's use condom ) study period least 48 hour afterwards Exclusion Criteria Patients schedule receive , prior 120 hour cisplatin AC , chemotherapeutic agent high moderate emetic risk Patients previously receive antineoplastic chemotherapy Patients schedule receive paclitaxel docetaxel first cycle chemotherapy Patients undergoing abdominal pelvic irradiation within 48 hour prior screen schedule receive abdominal pelvic irradiation screen 24 hour cisplatin AC administration Patients known prolactindependent tumour ( e.g . pituitary gland prolactinoma confirm prolactindependent breast cancer ) phaeochromocytoma Patients preexist vestibular disorder Patients treat regular antiemetic therapy include corticosteroid Patients receive inhaled corticosteroid , unless start one month prior expect date study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>